文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌当代结局:欧洲多中心大样本研究

Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study.
PubMed 文献 · BJU Int · 2025-05-21

该研究回顾性纳入6个欧洲三级转诊中心2015-2022年1918例接受TURBT的非肌层浸润性膀胱癌(NMIBC)患者,按EAU 2021标准分层。中位随访26个月,5年高级别复发率低危7.2%、中危17.3%、高危26.7%、极高危30.9%;5年进展率分别为3.9%、5.2%、13.6%、31.6%。接受足疗程膀胱灌注者高级别复发和进展风险显著降低。

要点

  • 高危/极高危NMIBC患者5年高级别复发和进展风险显著高于低危。
  • 足疗程膀胱灌注与更低的高级别复发(HR 0.3)和进展(HR 0.2)风险相关。
  • 真实世界中仅24.3%接受灌注的患者完成了足疗程灌注。

核心结论

  • 高危和极高危NMIBC患者面临显著更高的高级别复发和进展风险。
  • 坚持足疗程膀胱灌注对优化肿瘤学结局至关重要。

研究设计与样本

  • 回顾性多中心队列研究,纳入6个欧洲三级转诊中心2015-2022年1918例接受TURBT的NMIBC患者。
  • 按EAU 2021标准分为低危、中危、高危和极高危四组。
  • 采用累积发病率曲线和多变量竞争风险回归模型分析5年高级别复发和进展率。

主要发现

  • 患者构成:低危467例(24.3%)、中危582例(30.3%)、高危739例(38.5%)、极高危130例(6.8%)。
  • 中位随访26个月(IQR 12-46)。
  • 5年高级别复发率:低危7.2%、中危17.3%、高危26.7%、极高危30.9%;中危、高危、极高危相对低危风险分别高3倍、5倍、7倍(均P<0.001)。
  • 5年进展率:低危3.9%、中危5.2%、高危13.6%、极高危31.6%;高危和极高危相对低危风险分别高6倍和9倍(均P<0.001)。
  • 1001例(52.2%)接受膀胱灌注,其中244例(24.3%)完成足疗程灌注,其高级别复发风险(HR 0.3,P<0.001)和进展风险(HR 0.2,P=0.001)显著降低。

关键数值与推荐

  • 足疗程定义:卡介苗(BCG)为至少5次诱导灌注加至少2次维持灌注;丝裂霉素C为完成诱导灌注加至少11次维持灌注。

临床怎么用

  • 临床应依据EAU 2021风险分层对NMIBC患者进行个体化治疗和随访。
  • 应特别关注高危和极高危患者的高级别复发和进展风险。
  • 需采取措施提高膀胱灌注足疗程完成率以改善肿瘤学结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report real-world rates of non-muscle-invasive bladder cancer (NMIBC) recurrence and progression within a European multicentre cohort with detailed information on intravesical instillation courses, as contemporary data on oncological outcomes in NMIBC are limited. PATIENTS AND METHODS: A total of 1918 patients with NMIBC treated with transurethral resection of bladder tumour (TURBT) were retrospectively identified from six tertiary-referral European centres (2015-2022). Patients were stratified according to European Association of Urology 2021 criteria into low- (LR), intermediate- (IR), high- (HR) and very high-risk (VHR) categories. Cumulative incidence plots and multivariable competing risks regression models addressing 5-year rates of high-grade (HG) recurrence and progression were fitted. Sensitivity analyses focused on patients receiving intravesical instillations and tested for the effect of adequate course (Bacillus Calmette-Guérin: five or more induction + two or more maintenance instillations; mitomycin C: complete induction + ≥11 maintenance instillations). RESULTS: Of all NMIBC patients identified, 467 (24.3%) were LR vs 582 (30.3%) IR vs 739 (38.5%) HR vs 130 (6.8%) VHR. The median (interquartile range) follow-up after TURBT was 26 (12-46) months. The 5-year HG recurrence rates were 7.2% in LR vs 17.3% in IR vs 26.7% in HR vs 30.9% in VHR patients, resulting in a three-, five- and seven-fold higher risk of IR, HR and VHR, respectively, relative to LR (all P < 0.001). The 5-year progression rates were 3.9% in LR vs 5.2% in IR vs 13.6% in HR vs 31.6% in VHR patients, resulting in a six- and nine-fold higher risk for HR and VHR, respectively, relative to LR (all P < 0.001). In all, 1001 (52.2%) patients underwent intravesical instillations. Those receiving adequate instillation course (244/1001 [24.3%]) had lower HG-recurrence (hazard ratio 0.3, P < 0.001) and progression (hazard ratio 0.2, P = 0.001) risk. CONCLUSIONS: Patients with HR/VHR NMIBC face significantly higher HG recurrence and progression risks. While tailored treatment strategies are needed, adherence to adequate instillation course remains crucial for optimising oncological outcomes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Longoni M, Scilipoti P, De Angelis M, et al. Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre study. BJU Int. 2025. PMID: 40400172. doi:10.1111/bju.16780

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。